William R. Gillespie Case Study in the Use of Bayesian Hierarchical Modeling and Simulation for Design and Analysis of a Clinical Trial
|
M. C. Rosario (1), P. Jacqmin (2), Pat Dorr(1), Manos Perro (1) & Elna van der Ryst (1) A PK-PD-disease model to support the design of clinical trials of drugs for the treatment of HIV
|
Willem DeWinter(1), Joost DeJongh(1), Bart Ploeger(1), Richard Urquhart(2), Ian Moules(2), David Eckland(2), and Meindert Danhof(1) Disease progression modelling; application of population analysis to distinguish between symptomatic and protective treatment effects.
|
Joachim Stangier, Karl-Heinz Liesenfeld, Christiane Tillmann, Inaki Troconiz (#), Hans Guenter Schaefer Population pharmacokinetics/-dynamics of dabigatran, the active form of the new oral direct thrombin inhibitor dabigatran etexilate (BIBR 1048) in patients undergoing hip replacement
|
Brunhild Schiltmeyer1, Joachim Boos1, Matthias Schwab2, Thomas Mürdter2, Thomas Klingebiel3, G. Fleischhack5, Josef Vormoor1, Bernd Gruhn4 and Georg Hempel1 Population Pharmacokinetics of Intravenous Busulfan in Children
|
Christoffer W. Tornøe(1), Henrik Agersø(1), Henrik A. Nielsen(2), Henrik Madsen(2), and E. Niclas Jonsson(3) Population Pharmacokinetic Modelling of a Subcutaneous Depot for GnRH Antagonist Degarelix
|
Miller R, Kowalski KG, Liu J, Frame B, Burger PJ, Corrigan BW, Bockbrader HN, Lalonde R. Pregabalin Exposure-Adverse Event Analysis in Patients With Neuropathic Pain, Generalized Anxiety Disorder, or Partial Seizures
|
Duffull SB (1), Isbister GK (2), Dawson AH (2), Hackett LP (3), Whyte IM (2). Estimating population pharmacokinetic parameters when dose and dose-time are not known accurately
|
N. Hayashi(1), K. P. Zuideveld(1), P. Jordan(2), R. Gieschke(1) A Mechanism-Based PK/PD Model Predicts the Time-Course of Hematological responses for Epoetin beta
|
Estelle Kuhn and Marc Lavielle Maximum likelihood estimation in nonlinear mixed effects models
|
C. Hu, J.Y. Kim, K.H.P. Moore, M.E. Sale A Modeling Approach to Assessing Bioequivalence (BE) with Presence of Sparsely Sampled Subjects
|
Katarina Jelic, Morten Colding-Jørgensen Obesity and Insulin Resistance: A Fat Link
|
Emmanuelle Comets(1, 3), Kazumasa Ikeda(2), Yusuke Tanigawara(3) Comparison of the pharmacokinetics of S-1, an oral anticancer agent, in Western and Japanese patients
|
B. Vrijens(1-2), S.L. Mayer(1),R.Rode(3), R. Bertz(3), J. Urquhart(1) Dose-Timing Information Improves The Clinical Explanatory Power Of Data On Patient Adherence To Antiretroviral Drug Regimens
|
T. Kerbusch (1,2), U. Wählby (2), A. Skerjanec (3), P.A. Milligan (1), M.O. Karlsson(2) Assessment of the in vivo relative potency of the hydroxylated metabolite of darifenacin for the reduction of salivary flow using a population pharmacokinetic-pharmacodynamic meta-analysis
|
Lars Lindbom Parallel computing under Linux
|
MR, Ballester, MJ Barbanoj, R Antonijoan, M Yritia, M Valle. Absorption and plasma kinetics of multiple high oral doses of glucose: influence of glibenclamide.
|
Gianluca Nucci and Roberto Gomeni Design and power PK/PD experiments using very sparse data
|
Fredrik Jonsson and Niclas Jonsson A pharmacodynamic model for Scandinavian Stroke Scale data
|
Mark Sale Applications of Distributed computing in Drug development
|
K. Kowalski (1), M. Hutmacher (2) Evaluation of a Random Sparse Sampling Design: An Assessment of Power and Bias Using Simulation
|
Roy Anderson Patient adherence and the evolution of resistance to anti-viral agents
|
James B. Bassingthwaighte Developing Integrated Cell Systems
|